logo

BSX

Boston Scientific·NYSE
--
--(--)
--
--(--)

BSX fundamentals

Boston Scientific (BSX) released its earnings on Feb 4, 2026: revenue was 5.29B (YoY +15.90%), beat estimates; EPS was 0.8 (YoY +14.29%), beat estimates.
Revenue / YoY
5.29B
+15.90%
EPS / YoY
0.8
+14.29%
Report date
Feb 4, 2026
BSX Earnings Call Summary for Q4,2025
  • Q4 2025 Beat: 14.3% operational revenue growth, $0.80 EPS (+15%), and $3.659B free cash flow.
  • EP Dominance: 35% Q4 EP growth, 70% U.S. PFA penetration, and 29% WATCHMAN growth.
  • 2026 Outlook: 10-11% organic growth, 12-14% EPS growth, and $4.2B free cash flow.
  • Strategic Moves: Penumbra acquisition (Q2 2026), Siemens 4D ICE partnership, and CHAMPION trial potential for 20M patient expansion.
EPS
Revenue

Revenue & Expenses

BSX has released its 2025 Q4 earnings report, with revenue of 5.29B, reflecting a YoY change of 15.90%, and net profit of 670.00M, showing a YoY change of 19.22%. The Sankey diagram below clearly presents BSX's revenue sources and cost distribution.

Key Indicators

Boston Scientific (BSX) key financial stats and ratios, covering profitability, financial health, and leverage.
Boston Scientific (BSX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Boston Scientific (BSX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Boston Scientific (BSX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Boston Scientific (BSX) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Boston Scientific (BSX) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield